Jozsef Knoll, a Hungarian university professor, developed selegiline as an antidepressant medication in the 1950s. Its antidepressant action is related to its ability to inhibit the enzyme monoamine oxidase-B (MAO-B), thereby raising the brain level of monoamines, which function as neurotransmitters. These monoamines include dopamine, which is needed for normal muscle control, sex drive, cognition, and novelty seeking or adventurous behavior. Based on its actions on the brain's dopamine system, selegiline is also widely used as a medication to treat Parkinson's disease.
Was this article helpful?